Evaluation of longitudinal 12 and 24 month cognitive outcomes in premanifest and early Huntington's disease

被引:109
|
作者
Stout, Julie C. [1 ]
Jones, Rebecca [2 ]
Labuschagne, Izelle [1 ]
O'Regan, Alison M. [1 ]
Say, Miranda J. [3 ]
Dumas, Eve M. [4 ]
Queller, Sarah [1 ,5 ]
Justo, Damian [6 ,7 ]
Santos, Rachelle Dar [8 ]
Coleman, Allison [8 ]
Hart, Ellen P. [4 ]
Duerr, Alexandra [6 ,7 ]
Leavitt, Blair R. [8 ]
Roos, Raymund A. [4 ]
Langbehn, Doug R. [9 ,10 ]
Tabrizi, Sarah J. [3 ]
Frost, Chris [2 ]
机构
[1] Monash Univ, Sch Psychol & Psychiat, Melbourne, Vic 3800, Australia
[2] Univ London London Sch Hyg & Trop Med, Dept Med Stat, London WC1E 7HT, England
[3] UCL, UCL Inst Neurol, London, England
[4] Leiden Univ, Med Ctr, Dept Neurol, NL-2300 RA Leiden, Netherlands
[5] Queller Consulting, Dunedin, FL USA
[6] Hop La Pitie Salpetriere, APHP, Dept Genet & Cytogenet, Paris, France
[7] Hop La Pitie Salpetriere, APHP, INSERM, UMR S679, Paris, France
[8] Univ British Columbia, Dept Med Genet, Vancouver, BC, Canada
[9] Univ Iowa, Dept Psychiat, Iowa City, IA 52242 USA
[10] Univ Iowa, Dept Biostat Secondary, Iowa City, IA USA
来源
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY | 2012年 / 83卷 / 07期
关键词
CARRIERS; DECLINE; HD;
D O I
10.1136/jnnp-2011-301940
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background Deterioration of cognitive functioning is a debilitating symptom in many neurodegenerative diseases, such as Huntington's disease (HD). To date, there are no effective treatments for the cognitive problems associated with HD. Cognitive assessment outcomes will have a central role in the efforts to develop treatments to delay onset or slow the progression of the disease. The TRACK-HD study was designed to build a rational basis for the selection of cognitive outcomes for HD clinical trials. Methods There were a total of 349 participants, including controls (n=116), premanifest HD (n=117) and early HD (n=116). A standardised cognitive assessment battery (including nine cognitive tests comprising 12 outcome measures) was administered at baseline, and at 12 and 24 months, and consisted of a combination of paper and pencil and computerised tasks selected to be sensitive to cortical-striatal damage or HD. Each cognitive outcome was analysed separately using a generalised least squares regression model. Results are expressed as effect sizes to permit comparisons between tasks. Results 10 of the 12 cognitive outcomes showed evidence of deterioration in the early HD group, relative to controls, over 24 months, with greatest sensitivity in Symbol Digit, Circle Tracing direct and indirect, and Stroop word reading. In contrast, there was very little evidence of deterioration in the premanifest HD group relative to controls. Conclusions The findings describe tests that are sensitive to longitudinal cognitive change in HD and elucidate important considerations for selecting cognitive outcomes for clinical trials of compounds aimed at ameliorating cognitive decline in HD.
引用
收藏
页码:687 / 694
页数:8
相关论文
共 50 条
  • [1] Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis
    Tabrizi, Sarah J.
    Scahill, Rachael I.
    Durr, Alexandra
    Roos, Raymund A. C.
    Leavitt, Blair R.
    Jones, Rebecca
    Landwehrmeyer, G. Bernhard
    Fox, Nick C.
    Johnson, Hans
    Hicks, Stephen L.
    Kennard, Christopher
    Craufurd, David
    Frost, Chris
    Langbehn, Douglas R.
    Reilmann, Ralf
    Stout, Julie C.
    LANCET NEUROLOGY, 2011, 10 (01): : 31 - 42
  • [2] Testing a longitudinal compensation model in premanifest Huntington's disease
    Gregory, Sarah
    Long, Jeffrey D.
    Kloeppel, Stefan
    Razi, Adeel
    Scheller, Elisa
    Minkova, Lora
    Johnson, Eileanoir B.
    Durr, Alexandra
    Roos, Raymund A. C.
    Leavitt, Blair R.
    Mills, James A.
    Stout, Julie C.
    Scahill, Rachael I.
    Tabrizi, Sarah J.
    Rees, Geraint
    BRAIN, 2018, 141 : 2156 - 2166
  • [3] Apathy predicts rate of cognitive decline over 24 months in premanifest Huntington's disease
    Andrews, S. C.
    Langbehn, D. R.
    Craufurd, D.
    Durr, A.
    Leavitt, B. R.
    Roos, R. A.
    Tabrizi, S. J.
    Stout, J. C.
    PSYCHOLOGICAL MEDICINE, 2021, 51 (08) : 1338 - 1344
  • [4] Longitudinal evaluation of cognitive disorder in Huntington's disease
    Snowden, J
    Craufurd, D
    Griffiths, H
    Thompson, J
    Neary, D
    JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY, 2001, 7 (01) : 33 - 44
  • [5] Hair and salivary cortisol and their relationship with lifestyle, mood and cognitive outcomes in premanifest Huntington’s disease
    Travis Cruickshank
    Tenielle Porter
    Simon M. Laws
    Mel Ziman
    Danielle M. Bartlett
    Scientific Reports, 11
  • [6] A novel cognitive-neurophysiological state biomarker in premanifest Huntington's disease validated on longitudinal data
    Christian Beste
    Ann-Kathrin Stock
    Vanessa Ness
    Rainer Hoffmann
    Carsten Lukas
    Carsten Saft
    Scientific Reports, 3
  • [7] HIPPOCAMPAL ABNORMALITIES IN PREMANIFEST AND EARLY STAGE HUNTINGTON'S DISEASE
    Harris, Kate
    Mason, Sarah
    Barker, Roger
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2016, 87 : A51 - A51
  • [8] Hair and salivary cortisol and their relationship with lifestyle, mood and cognitive outcomes in premanifest Huntington's disease
    Cruickshank, Travis
    Porter, Tenielle
    Laws, Simon M.
    Ziman, Mel
    Bartlett, Danielle M.
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [9] A novel cognitive-neurophysiological state biomarker in premanifest Huntington's disease validated on longitudinal data
    Beste, Christian
    Stock, Ann-Kathrin
    Ness, Vanessa
    Hoffmann, Rainer
    Lukas, Carsten
    Saft, Carsten
    SCIENTIFIC REPORTS, 2013, 3
  • [10] Resting-state connectivity stratifies premanifest Huntington’s disease by longitudinal cognitive decline rate
    Pablo Polosecki
    Eduardo Castro
    Irina Rish
    Dorian Pustina
    John H. Warner
    Andrew Wood
    Cristina Sampaio
    Guillermo A. Cecchi
    Scientific Reports, 10